Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.55 |
| ▸ | CETP | P11597 | 1/20 | 0.55 |
| ▸ | PPARG | P37231 | 2/20 | 0.54 |
| ▸ | PPARA | Q07869 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | FDFT1 | P37268 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10106193 | 0.95 | PPARA (0.60) | LTA4HCETPPPARGPPARAFDFT1 | |
| SCHEMBL2874471 | 0.93 | PPARA (0.62) | LTA4HCETPPPARGPPARA | |
| SCHEMBL10624215 | 0.93 | PPARA (0.62) | LTA4HCETPPPARGPPARA | |
| SCHEMBL23085167 | 0.93 | PPARA (0.62) | LTA4HCETPPPARGPPARA | |
| SCHEMBL29959530 | 0.93 | PPARA (0.62) | LTA4HCETPPPARGPPARA | |
| SCHEMBL11508066 | 0.92 | PPARA (0.61) | LTA4HCETPPPARGPPARAFDFT1 | |
| SCHEMBL1696397 | 0.89 | KDM4E (0.55) | LTA4HCETPKDM4EALDH1A1TDP1 | |
| SCHEMBL10106196 | 0.88 | FDFT1 (0.54) | LTA4HCETPPPARGPPARAKDM4E | |
| SCHEMBL9819438 | 0.87 | PPARA (0.63) | CETPPPARGPPARA | |
| SCHEMBL21770981 | 0.87 | KDM4E (0.54) | LTA4HCETPKDM4EALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9844540-B2 | Combination therapies for treating cancer | REDHILL BIOPHARMA LTD. (IL) | 2017-12-19 | — | — | US | disclosed |
| US-20170095460-A1 | COMBINATION THERAPIES FOR TREATING CANCER | REDHILL BIOPHARMA LTD. (IL) | 2017-04-06 | — | — | US | disclosed |
| US-20120214798-A1 | Novel Ethanediamone Hepcidine Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
| US-20120122870-A1 | Treatment Of Ischemia-Reperfusion Injury | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120095004-A1 | Sphingosine Kinase Inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2012-04-19 | — | — | US | disclosed |
| US-20100137315-A1 | Sphingosine Kinase Inhibitors and Methods of Their Use | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2010-06-03 | — | — | US | disclosed |
| CN-1069962-A | The preparation method of parasiticidal cyclopropyl-replacement two (aromatic base) compound | FMC CORP (US) | 1993-03-17 | — | — | CN | disclosed |
| CN-1069168-A | Method for controlling insects and acarids | FMC CORP (US) | 1993-02-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095004-A1 | Sphingosine Kinase Inhibitors | SPHK1, SPHK2, S1PR1 | LTA4H 944/4885CETP 402/4885PPARG 3791/4885 |
| US-20120122870-A1 | Treatment Of Ischemia-Reperfusion Injury | SPHK1, SPHK2, S1PR2 | LTA4H 1008/4885CETP 582/4885PPARG 3868/4885 |
| US-20100137315-A1 | Sphingosine Kinase Inhibitors and Methods of Their Use | SPHK1, SPHK2, S1PR2 | LTA4H 668/4885CETP 424/4885PPARG 2422/4885 |
| US-20170095460-A1 | COMBINATION THERAPIES FOR TREATING CANCER | KRAS, ACE, TPMT | LTA4H 4654/4885CETP 3581/4885PPARG 766/4885 |
| US-20120214798-A1 | Novel Ethanediamone Hepcidine Antagonists | HAMP, SLC40A1, FTH1 | LTA4H 137/4885CETP 1620/4885PPARG 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.